118306-89-1

Basic information

• Product Name: 4-PIPERAZIN-1-YL-QUINOLINE
• Synonyms: 1-(4-Quinolinyl)piperazine;1-(4-Quinolyl)piperazine; 4-(1-Piperazinyl)quinoline; 4-Piperazinylquinoline
• CAS NO: 118306-89-1
• Molecular Formula: C₁₃H₁₅N₃
• Molecular Weight: 213.28
• Mol File: 118306-89-1.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 403.7°C at 760 mmHg
• Flash Point: 198°C
• Appearance: /
• Density: 1.152g/cm³
• Vapor Pressure: 9.98E-07mmHg at 25°C
• Refractive Index: 1.628
• PKA: 10.14±0.46(Predicted)
• CAS DataBase Reference: 4-PIPERAZIN-1-YL-QUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PIPERAZIN-1-YL-QUINOLINE(118306-89-1)
• EPA Substance Registry System: 4-PIPERAZIN-1-YL-QUINOLINE(118306-89-1)

Safety Data

• Hazardous Substances Data: 118306-89-1(Hazardous Substances Data)

Usage

General Description

4-PIPERAZIN-1-YL-QUINOLINE is a chemical compound that consists of a piperazine moiety attached to a quinoline ring. It has several potential biological activities and is often used in medicinal chemistry as a structural scaffold for the development of new drugs. Specifically, this compound has been explored for its potential as an antipsychotic, antidepressant, and antihistamine, as well as for its ability to modulate serotonin and dopamine receptors in the brain. Additionally, 4-PIPERAZIN-1-YL-QUINOLINE has been studied for its potential as an anti-inflammatory and anti-cancer agent. Its versatile structural features make it a valuable template for the synthesis and development of novel pharmaceutical compounds with varied biological activities.

InChI:InChI=1/C13H15N3/c1-2-4-12-11(3-1)13(5-6-15-12)16-9-7-14-8-10-16/h1-6,14H,7-10H2

Upstream product

• 611-35-8 4-chloroquinoline 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 110-85-0 piperazine 

Relevant articles and documents

Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors

A structure based medium throughput virtual screening campaign of BITS-Pilani in house chemical library to identify novel binders of Mycobacterium tuberculosis gyrase ATPase domain led to the discovery of a quinoline scaffold. Further medicinal chemistry explorations on the right hand core of the early hit, engendered a potent lead demonstrating superior efficacy both in the enzyme and whole cell screening assay. The binding affinity shown at the enzyme level was further corroborated by biophysical characterization techniques. Early pharmacokinetic evaluation of the optimized analogue was encouraging and provides interesting potential for further optimization.

Discovery of β2 adrenergic receptor ligands using biosensor fragment screening of tagged wild-type receptor

G-protein coupled receptors (GPCRs) are the primary target class of currently marketed drugs, accounting for about a quarter of all drug targets of approved medicines. However, almost all the screening efforts for novel ligand discovery rely exclusively on cellular systems overexpressing the receptors. An alternative ligand discovery strategy is a fragment-based drug discovery, where low molecular weight compounds, known as fragments, are screened as initial starting points for optimization. However, the screening of fragment libraries usually employs biophysical screening methods, and as such, it has not been routinely applied to membrane proteins. We present here a surface plasmon resonance biosensor approach that enables, cell-free, label-free, fragment screening that directly measures fragment interactions with wild-type GPCRs. We exemplify the method by the discovery of novel, selective, high affinity antagonists of human β2 adrenoceptor.

Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl) ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: Potent in vivo activity in Parkinson's disease anima

Here we report structure - activity relationship study of a novel hybrid series of compounds where structural alteration of aromatic hydrophobic moieties connected to the piperazine ring and bioisosteric replacement of the aromatic tetralin moieties were